BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne's solid tumor franchise. Mark Lanasa, M.D., Ph.

Business Wire • Oct 24, 2026

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GE.

Business Wire • Oct 23, 2026

BeOne Medicines: Brukinsa And Tevimbra Face A High Bar

BeOne Medicines AG is a fast-growing oncology company and a Wall Street favorite. Tevimbra, its PD-1 inhibitor, helped drive growth, with Q2 revenue rising 10.8% QoQ and 18.1% YoY to $228.5 million. BeOne's rich pipeline includes BGB-B2033, BG-C477, and BGB-58067, with clinical data scheduled for presentation at the 2026 ESMO Congress, taking place October 23-27.

Seeking Alpha • Oct 23, 2026

BeOne Stock Breaks Out With Visions Of 177% Earnings Growth. This Telltale Clue Bodes Well.

Oncology-focused biotech firm BeOne Medicines pops into buy range, boosted by strong demand and stellar earnings growth.

Investors Business Daily • Oct 22, 2026

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company's website at https://ir.beonemedicines.com.To ensure a.

Business Wire • Oct 22, 2026

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-bre.

Business Wire • Oct 19, 2026

All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy

BeOne Medicines Ltd. - Sponsored ADR (ONC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research • Oct 15, 2026

New Strong Buy Stocks for October 15th

KMX, ACIC, ONC, ODD and WES have been added to the Zacks Rank #1 (Strong Buy) List on October 15, 2026.

Zacks Investment Research • Oct 15, 2026

Biotech Leader BeOne Medicines Poised To Hit Early Buy Points

Biotech leader BeOne stock is poised to hit multiple buy points. Its blockbuster drug generated $1.2 billion in sales in the second quarter.

Investors Business Daily • Oct 1, 2026

BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

BeOne Medicines AG (ONC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026